Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan liposomal - Jiangsu Hengrui Medicine

Drug Profile

Irinotecan liposomal - Jiangsu Hengrui Medicine

Alternative Names: HR-070803

Latest Information Update: 30 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Pancreatic cancer
  • Phase II/III Colorectal cancer
  • Phase II Oesophageal cancer

Most Recent Events

  • 20 Apr 2024 The First Affiliated Hospital with Nanjing Medical University plans a phase II trial for Pancreatic cancer (Combiation therapy, Adjuvant therapy), in April 2024 (NCT06383078)
  • 04 Dec 2023 Preregistration for Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) (unspecified route), prior to December 2023 (Jiangsu HengRui Medicine pipeline, December 2023)
  • 14 Aug 2023 Phase-II/III clinical trials in Colorectal cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable, First-line therapy, Combination therapy) in China (IV) (NCT05945901)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top